Considerations on the Off-label Use of Ketamine as a Treatment for Mood Disorders
Samuel T. Wilkinson, Gerard Sanacora
JAMA August 14, 2017 DOI: 10.1001/jama.2017.10697 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Viewpoint Peer reviewed |
|---|---|
| Topics | Anxiety Ketamine Esketamine |
| Keywords | Mood disorders Statement logic Intensive care medicine Medline Electroconvulsive therapy studies |
| Citations | 36 |
| Key points | A consensus statement addresses important issues related to the clinical use of ketamine for psychiatric disorders and provides suggestions for addressing remaining concerns. |
Abstract
This Viewpoint summarizes a number of important issues related to the clinical use of ketamine for the treatment of psychiatric disorders addressed in the consensus statement and provides suggestions for addressing remaining concerns.
Citations in the library
Cited by 22
- Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor Molecular Psychiatry May 7, 2021
- Molecular mechanisms of the rapid-acting and long-lasting antidepressant actions of (R)-ketamine. Biochemical Pharmacology July 1, 2020
- Acute and Longer-Term Outcomes Using Ketamine as a Clinical Treatment at the Yale Psychiatric Hospital The Journal of Clinical Psychiatry July 23, 2018
- The Antidepressant Effect of Ketamine Is Dampened by Concomitant Benzodiazepine Medication Frontiers in Psychiatry August 28, 2020
- Pharmacodynamic Interactions Between Ketamine and Psychiatric Medications Used in the Treatment of Depression: A Systematic Review The International Journal of Neuropsychopharmacology June 25, 2021
and 17 more in the library
Cites 5
- Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression American Journal of Psychiatry October 1, 2015
- A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders JAMA Psychiatry March 1, 2017
- A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression American Journal of Psychiatry April 8, 2016
- Dose-Related Effects of Adjunctive Ketamine in Taiwanese Patients with Treatment-Resistant Depression. Neuropsychopharmacology December 2017
- A survey of the clinical, off-label use of ketamine as a treatment for psychiatric disorders American Journal of Psychiatry July 1, 2017